NOTICES

• Notice of Pre-application Webinar for PAR-17-206 and PAR-17-207 Alliance of Glycobiologists for Cancer Research (U01) (NOT-CA-17-044)
  National Cancer Institute

• Notice of a Pre-Application Technical Assistance Webinar for RFA-CA-17-023 "Integration and Validation of Emerging Technologies to Accelerate Cancer Research (R33)" (NOT-CA-17-045)
  National Cancer Institute

• Reporting Preprints and Other Interim Research Products (NOT-OD-17-050)
  National Institutes of Health

• Notice of Correction of Key Dates for PAR-17-173 "Mind and Body Intervention Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24)"
  (NOT-AT-17-005)
  National Center for Complementary and Integrative Health

• Notice of PA-16-282 and PA-16-283 Cancellation (NOT-HS-17-009)
  Agency for Healthcare Research and Quality

• Notice to Extend PA-14-290 and PA-14-291 (NOT-HS-17-010)
  Agency for Healthcare Research and Quality

• Notice of Expiration for RFA-HG-16-016 "BD2K Open Educational Resources for Skills Development in Biomedical Big Data Science (R25)" (NOT-RM-17-008)
  NIH Roadmap Initiatives
  The Common Fund/Office of Strategic Coordination

• Notice of Expiration for RFA-ES-16-010 "Big Data to Knowledge (BD2K) Community-Based Data and Metadata Standards Efforts (R24)" (NOT-RM-17-009)
  NIH Roadmap Initiatives
  The Common Fund/Office of Strategic Coordination

• Notice of Expiration for RFA-ES-16-011 "BD2K Research Education Curriculum Development: Data Science Overview for Biomedical Scientists (R25)" (NOT-RM-17-010)
  NIH Roadmap Initiatives, National Institute of Environmental Health Sciences, The Common Fund/Office of Strategic Coordination

• Notice of Expiration for RFA-CA-16-020 "BD2K Support for Meetings of Data Science Related Organizations (U13)" (NOT-RM-17-011)
  NIH Roadmap Initiatives, The Common Fund/Office of Strategic Coordination

• Changes to RFA-TR-17-003: Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules (UG3/UH3) (NOT-TR-17-013)
  National Center for Advancing Translational Sciences

• Changes to RFA-TR-17-002 "Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UG3/UH3) " (NOT-TR-17-014)
  National Center for Advancing Translational Sciences

• Notice Announcing Pre-Application Webinar and Frequently Asked Questions (FAQ) for RFA-OD-17-003, Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control (U54) (NOT-OD-17-046)
  National Institutes of Health

• Notice Announcing Pre-Application Webinar and Frequently Asked Questions (FAQ) for RFA-OD-17-002, Center for Coordination of Analytics, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54) (NOT-OD-17-047)
  National Institutes of Health

• NIH Operates Under a Continuing Resolution (NOT-OD-17-048)
  National Institutes of Health

• Interim Guidance on Salary Limitation for Grants and Cooperative Agreements (NOT-OD-17-049)
  National Institutes of Health

• NIAID Omnibus Broad Agency Announcement No. HHS-NIH-NIAID-BAA2017-1 (NOT-AI-17-019)
  National Institute of Allergy and Infectious Diseases

Week of April 3, 2017
• Request for Information (RFI): Input for National Cancer Institute (NCI) Cancer Moonshot Implementation Team for Fusion Oncoproteins in Childhood Cancers
  [NOT-CA-17-041]
  National Cancer Institute

• NCI will support training in Patient-Oriented Research through K08 Awards and increase K08 Salary and Research Support
  [NOT-CA-17-042]
  National Cancer Institute

• Notice of NCIs Withdrawal from Participation in PA-16-198 "Mentored Patient-Oriented Research Career Development Award (Parent K23)"
  [NOT-CA-17-043]
  National Cancer Institute

• RESCINDED - NICHD Will No Longer Participate in the Parent NIH Exploratory/Developmental Research Grant (R21) Funding Opportunity Announcement (PA-16-161)
  [NOT-HD-17-006]
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

• Revision: NICHD Will No Longer Participate in the Parent NIH Exploratory/Developmental Research Grant (R21) Funding Opportunity Announcement (PA-16-161)
  [NOT-HD-17-007]
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

• Notice of Change to Eligibility for RFA-HL-17-022 "Maximizing the Scientific Value of the NHLBI Biorepository: Scientific Opportunities for Exploratory Research (R21)"
  [NOT-HL-17-494]
  National Heart, Lung, and Blood Institute

• Notice of Change to Key Dates in PAR-17-093 "Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01)"
  [NOT-CA-17-034]
  National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases

• Notice of Change in the Eligibility of Foreign Components in PAR-14-260 "Interventions for Health Promotion and Disease Prevention in Native American Communities (R01)"
  [NOT-CA-17-038]
  National Cancer Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Institute of Dental and Craniofacial Research

• Notice of Change to Key Dates in PAR-17-128 "Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3)"
  [NOT-CA-17-039]
  National Cancer Institute

• Notice of Change to Key Dates in PAR-17-129 "Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01)"
  [NOT-CA-17-040]
  National Cancer Institute

• Notice of Clarification of Applications Accepted in Response to PAR-16-034, Ancillary Studies to Major Ongoing Clinical Research Studies to Advance Areas of Scientific Interest within the Mission of the NIDDK (R01)
  [NOT-DK-17-009]
  National Institute of Diabetes and Digestive and Kidney Diseases

• Notice of Modifications to PAR-16-361 Research Initiative for Scientific Enhancement (RISE) (R25)
  [NOT-GM-17-003]
  National Institute of General Medical Sciences

• Notice of NHGRI Participation in PAR-15-287 "Opportunities for Collaborative Research at the NIH Clinical Center (U01)"
  [NOT-HG-17-001]
  National Human Genome Research Institute

• Notice of Requirement for Predoctoral T32 Training Programs Formerly Supported by NIGMS that Intend to apply to the Jointly Sponsored Predoctoral Training Program in the Neurosciences (JSPTPN)
  [NOT-NS-17-018]
  National Institute of Neurological Disorders and Stroke

• Notice of NOT-PM-16-006 Cancellation: Revised Guidance to be Published at a Later Date
  [NOT-PM-17-003]
  National Institutes of Health

• Update and Clarification: NIH Continuous Submission Policy
  [NOT-OD-17-042]
  National Institutes of Health

• Notice of Termination of PAR-16-399 "Mentored Patient-Oriented Research Career Development Award to Promote Diversity (K23)"
  [NOT-CA-17-033]
  National Cancer Institute
REQUEST FOR APPLICATIONS

**TITLE:** Integration and Validation of Emerging Technologies to Accelerate Cancer Research (R33)  
(RFA-CA-17-023)  
**SPONSOR:** National Cancer Institute  
**Synopsis:** This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot™ Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research on the advanced development and rigorous validation of new enabling technologies/tools/capabilities with a transformative potential for cancer research and clinical oncology. Specifically, this FOA targets the following four areas designated as scientific priorities: Enhanced experimental and analytical capabilities addressing complexities of cancer development; New capabilities advancing precise clinical diagnosis of cancer patients; Novel predictive ex vivo and/or in silico modeling approaches; and New technologies/approaches to improve biospecimen and data quality. Applications must be focused on one of these areas and must be based on comprehensive preliminary data substantiating the potential of the proposed technologies/tools/capabilities and the functionality their contributing components. Essential aspect is a rigorous technical validation to ensure that the transformative, enabling potential of the proposed technologies/tools/capabilities for cancer research and/or clinical care is thoroughly verified by the end of the project period.  
Application Receipt Date(s): May 10, 2017

**TITLE:** NIDCR Dental Specialty and PhD Program (DSPP)(K12)  
(RFA-DE-18-003)  
**SPONSOR:** National Institute of Dental and Craniofacial Research  
**Application Receipt Date(s):** July 3, 2017

**TITLE:** Consumer Assessment of Healthcare Providers and Systems V (CAHPS V) (U18)  
(RFA-HS-17-010)  
**SPONSOR:** Agency for Healthcare Research and Quality  
**Synopsis:** The purpose of this RFA is to continue the work of the Consumer Assessment of Healthcare Providers and Systems (CAHPS) program which AHRQ began in 1995. Specifically, this RFA solicits research to be performed within five broad areas: a) Advancing the science of consumer assessment of patient experience; b) Continued innovation to ensure relevance to health services delivery and survey best practices; c) Reporting patient experience data; d) Quality improvement (QI) studies; and e) Developing internal and external program communication strategies. Each of these areas is described in detail in Part 2. Full Text of the Announcement.  
Application Receipt Date(s): May 26, 2017

**TITLE:** Intensive Longitudinal Analysis of Health Behaviors: Leveraging New Technologies to Understand Health Behaviors (U01)  
(RFA-OD-17-004)  
**SPONSOR:** Office of Behavioral and Social Science Research, National Cancer Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Institute of Mental Health  
**Synopsis:** This Funding Opportunity Announcement (FOA) encourages applications to support Research Projects studying factors that influence key health behaviors at the individual level, using intensive longitudinal data collection and analytic methods. The network will also assess how study results can be leveraged to introduce innovations into longstanding
behavioral theories to advance the field of theory-driven behavior change interventions.

Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Intensive Longitudinal Analysis of Health Behaviors: Leveraging New Technologies to Understand Health Behaviors (U24)  
  **SPONSOR:** Office of Behavioral and Social Science Research, **National Cancer Institute**, National Institute on Alcohol Abuse and Alcoholism, National Institute of Biomedical Imaging and Bioengineering, National Institute on Drug Abuse, National Institute of Mental Health  
  **Synopsis:** This Funding Opportunity Announcement (FOA) invites applications to establish a Research Coordinating Center (RCC) to facilitate and support the Intensive Longitudinal Health Behaviors Initiative. The goal of this initiative is to support collaborative research projects studying factors that influence key health behaviors at the individual level, using intensive longitudinal data collection and analytic methods, as well as to further advance research through the broad dissemination of data with the research community, as appropriate. The network will also assess how study results can be leveraged to introduce innovations into longstanding behavioral theories to advance the field of theory-driven behavior change interventions. The RCC will coordinate common activities of the network including communications, meetings, governance, and the development of methods harmonization, data integration, and dissemination.

Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54)  
  **SPONSOR:** U.S. Food and Drug Administration, Center for Tobacco Products, **National Cancer Institute**, National Heart, Lung, and Blood Institute, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, Office of Disease Prevention  
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for Tobacco Centers of Regulatory Science (TCORS) to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Application Receipt Date(s): July, 19, 2017

- **TITLE:** Revision Applications to NCI-supported R01 Awards to Include Research on the NCI's Provocative Questions (R01)  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI R01 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-17-017 (R01) and RFA-CA-17-018(R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent R01 award.

Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Revision Applications to National Cancer Institute (NCI)-supported U01 Awards to Include Research on the NCI's Provocative Questions (U01)  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI U01 research project awards. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-17-017 (R01) and RFA-CA-17-018 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent U01 award.

Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Revision Applications to National Cancer Institute (NCI)-supported P01 Awards to Include Research on the NCI's Provocative Questions (P01)  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** This Funding Opportunity Announcement (FOA) invites revision applications from currently funded NCI P01 Program Projects. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published in RFA-CA-17-017 and RFA-CA-17-018 that are intended for new R01 and R21 applications, respectively. This FOA encourages research that directly addresses PQs, including research that helps validate
PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to a new research project expanding the scope, yet integrated into the overall theme, of the entire parent P01 award.
Application Receipt Date(s): Multiple dates, see announcement

**TITLE:** Revision Applications to National Cancer Institute (NCI)-supported P50 Awards to Include Research on the NCI's Provocative Questions (P50)  
(RFA-CA-17-022)
**SPONSOR:** National Cancer Institute
**Synopsis:** This Funding Opportunity Announcement (FOA) invites revision applications from currently funded NCI P50 Specialized Centers. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published in RFA-CA-17-017 and RFA-CA-17-018 that are intended for new R01 and R21 applications, respectively. This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to a new research project expanding the scope, yet integrated into the overall theme, of the entire parent P50 award.
Application Receipt Date(s): Multiple dates, see announcement

**TITLE:** Center for Coordination of Analytics, Science, Enhancement , and Logistics (CASEL) in Tobacco Regulatory Science (U54)  
(RFA-OD-17-002)
**SPONSOR:** National Institutes of Health, U.S. Food and Drug Administration, Center for Tobacco Products, Food and Drug Administration, National Institute on Drug Abuse, Office of Disease Prevention
**Synopsis:** This Funding Opportunity Announcement (FOA) solicits applications for a Center for Coordination of Analytics, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science. CASEL will support the scientific research programs funded by the Food and Drug Administration (FDA) Center for Tobacco Products (CTP), and will facilitate synthesis, coordination and communications of research and career enhancement within those programs. The overall objective of CASEL is to support research programs that can inform the FDA CTP in tobacco product regulatory activities and actions. Through leadership, coordination, and facilitation of collaborative efforts, CASEL can accelerate the advancement of science relevant to the Family Smoking Prevention and Tobacco Control Act (FSPTCA). The NIH and the FDA have formed an interagency partnership to foster research relevant to FDA's tobacco regulatory authorities. The award under this FOA will be administered by the NIH using designated funds from the FDA CTP for tobacco regulatory science mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.
Application Receipt Date(s): July 19, 2017

**TITLE:** Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54)  
(RFA-OD-17-003)
**SPONSOR:** U.S. Food and Drug Administration, Center for Tobacco Products, Food and Drug Administration, National Cancer Institute, National Heart, Lung, and Blood Institute, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, Office of Disease Prevention
**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for Tobacco Centers of Regulatory Science (TCORS) to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
Application Receipt Date(s): July 19, 2017

**TITLE:** Research Answers to NCI's Provocative Questions (R01)  
(RFA-CA-17-017)
**SPONSOR:** National Cancer Institute
**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. The current issuance of the PQ Initiative includes an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.
Application Receipt Date(s): Multiple dates, see announcement

**TITLE:** Research Answers to NCI's Provocative Questions (R21)  
(RFA-CA-17-018)
**SPONSOR:** National Cancer Institute
**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions...
The current issuance of the PQ Initiative includes an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Neoantigen-Based Therapeutic Targeting of Head and Neck Cancers (R01)  
  **SPONSOR:** National Institute of Dental and Craniofacial Research  
  Application Receipt Date(s): June 19, 2017

- **TITLE:** Neuroskeletal Biology of the Dental and Craniofacial Skeletal System (R01)  
  **SPONSOR:** National Institute of Dental and Craniofacial Research  
  Application Receipt Date(s): September 28, 2017

- **TITLE:** Neuroskeletal Biology of the Dental and Craniofacial Skeletal System (R21)  
  **SPONSOR:** National Institute of Dental and Craniofacial Research  
  Application Receipt Date(s): September 28, 2017

- **TITLE:** Limited Competition: NIMHD Endowment Program for Increasing Research and Institutional Resources (S21)  
  **SPONSOR:** National Institute on Minority Health and Health Disparities  
  Application Receipt Date(s): May 1, 2017

- **TITLE:** NIMHD Specialized Centers of Excellence for Research on Minority Health and Health Disparities (U54)  
  **SPONSOR:** National Institute on Minority Health and Health Disparities  
  Application Receipt Date(s): May 15, 2017

**PROGRAM ANNOUNCEMENTS**

- **TITLE:** Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01)  
  **SPONSOR:** National Cancer Institute, National Human Genome Research Institute, National Institute of Dental and Craniofacial Research  
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.

- **TITLE:** Fostering Research Training and Education Programs for Native American Students at NCI-designated Cancer Centers (Admin Supp)  
  **SPONSOR:** National Cancer Institute  
  Application Receipt/Submission Date(s): April 28, 2017, by 5:00 PM local time of the applicant institution.

- **TITLE:** Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21)  
  **SPONSOR:** National Cancer Institute, National Human Genome Research Institute, National Institute of Dental and Craniofacial Research  
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.

- **TITLE:** Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01)  
  **SPONSOR:** National Cancer Institute  
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.

- **TITLE:** Mechanisms and Consequences of Sleep Disparities in the U.S. (R01) (R21)  
  **SPONSOR:** National Institute on Minority Health and Health Disparities, National Center for Complementary and Integrative Health  
  Application Receipt/Submission Date(s): July 11, 2017, July 11, 2018, July 11, 2019, by 5:00 PM local time.
Synopsis: This Funding Opportunity Announcement (FOA) invites applications investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption.

Application Receipt/Submission Date(s): Multiple dates, see announcement

TITLE: Advancing the Science of Geriatric Palliative Care (R21)

SPONSOR: National Institute on Aging, National Center on Complementary and Integrative Health, National Institute on Minority Health and Health Disparities, National Institute of Nursing Research

Application Receipt/Submission Date(s): Multiple dates, see announcement

TITLE: Advancing the Science of Geriatric Palliative Care (R01)

SPONSOR: National Institute on Aging, National Center for Complementary and Integrative Health, National Institute on Minority Health and Health Disparities, National Institute of Nursing Research

Application Receipt/Submission Date(s): Multiple dates, see announcement

TITLE: Centers for AIDS Research (P30)

SPONSOR: National Institute of Allergy and Infectious Diseases, John E. Fogarty International Center, National Cancer Institute

Application Receipt/Submission Date(s): August 1, 2017; August 17, 2018; August 17, 2019, by 5:00 PM local.

TITLE: Developmental Centers for AIDS Research (P30)

SPONSOR: National Institute of Allergy and Infectious Diseases, John E. Fogarty International Center, National Cancer Institute

Application Receipt/Submission Date(s): August 1, 2017; August 17, 2018; August 17, 2019, by 5:00 PM local time.

TITLE: Innovative Research in Cancer Nanotechnology (IRCN) (R01)

SPONSOR: National Cancer Institute

Application Receipt/Submission Date(s): November 21, 2017; May 23, 2018; November 20, 2018; May 23, 2019, November 21, 2019, May 21, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

TITLE: Mechanisms of Alcohol-associated Cancers (R21)

SPONSOR: National Institute on Alcohol Abuse and Alcoholism, National Cancer Institute

Synopsis: This Funding Opportunity Announcement (FOA) invites applications investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption.

Application Receipt/Submission Date(s): Multiple dates, see announcement

TITLE: Mechanisms of Alcohol-associated Cancers (R01)

SPONSOR: National Institute on Alcohol Abuse and Alcoholism, National Cancer Institute

Synopsis: This Funding Opportunity Announcement (FOA) invites applications investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption.

Application Receipt/Submission Date(s): Multiple dates, see announcement

TITLE: Supplements for Validating the Use of Automated Sources of Residential Histories in Cancer Epidemiology Cohorts (Admin Supp)

SPONSOR: National Cancer Institute
Synopsis: The National Cancer Institute (NCI) announces an opportunity for awardees holding eligible NCI-funded awards to request administrative supplement funding to support augmented efforts to refine automated methodologies to obtain more accurate and reliable lifetime residential history data and linkages that would enhance cancer research.
Application Receipt/Submission Date(s): June 1, 2017

- **TITLE:** Supplement Opportunity to Support Population-Based Research Studies of Rare Cancers (Admin Supp) (PA-17-223)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for supplemental funding to eligible NCI awards so that involved personnel (awardees) can advance their efforts to gain needed knowledge on rare cancers. The goal is to support population-based, hypothesis-testing studies that will increase our understanding of the etiology or post-diagnosis outcomes of rare cancers.
  Application Receipt/Submission Date(s): June 1, 2017

- **TITLE:** Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies (Admin Supp) (PA-17-224)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The National Cancer Institute (NCI) hereby notifies Program Director(s)/Principal Investigator(s) holding eligible awards (as specified in this FOA) that funds are available for administrative supplements to prepare and deposit individual-level data from cancer epidemiology studies into NCI-supported, controlled-access databases including the Cancer Epidemiology Data Repository (CEDR) and the database of Genotypes and Phenotypes (dbGaP). Sharing of research data will accelerate scientific discovery and increase opportunities for collaboration to provide new clues to cancer etiology, determine risk factors, and improve cancer survivorship.
  Application Receipt/Submission Date(s): June 1, 2017

- **TITLE:** Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24) (PAR-17-172)
  **SPONSOR:** National Center for Complementary and Integrative Health
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Mind and Body Intervention Multi-Site Clinical Trial Data Coordinating Center (U24) (PAR-17-173)
  **SPONSOR:** National Center for Complementary and Integrative Health
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3) (PAR-17-174) (PAR-17-175)
  **SPONSOR:** National Center for Complementary and Integrative Health
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Inter-organelle Communication in Cancer (R01) (PAR-17-203)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Inter-organelle Communication in Cancer (R21) (PAR-17-204)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Alliance of Glycobiologists for Cancer Research: Translational Tumor Glycomics Laboratories (U01) (PAR-17-206)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to continue support for the program referred to as the “Alliance of Glycobiologists for Cancer Research” (http://glycomics.cancer.gov). Through this FOA, the NCI encourages research projects to elucidate how changes in cellular carbohydrates may promote cancer initiation and progression and use this information to identify glycans-based abnormalities to serve as biomarkers for early cancer detection or risk assessment. These changes may be studied at the level of glycoproteins, glycolipids, glycosaminoglycans, and/or their binding proteins. In their applications, applicants are encouraged to address the ability...
of these biomarker candidates to accurately distinguish individuals with cancer from those without. It is expected that the most promising biomarker candidates will ultimately be tested in clinical validation studies, although such validation studies are not required for the proposed projects. All investigators with appropriate expertise and capabilities, irrespective of any prior association with this Alliance, are encouraged to consider applying to this FOA.

Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Alliance of Glycobiologists for Cancer Research: Biological Tumor Glycomics Laboratories (U01) (PAR-17-207)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) is intended to support research applications that are focused on mechanisms that mediate alterations in glycosylation during oncogenesis. The goal of this FOA is to advance our knowledge of altered glycosylation or other modifications in carbohydrate structure in cancer to determine whether it is the cause or the result of neoplastic transformation. Because the research is intended to examine the biology of how modifications in carbohydrate structure influence malignancy during different stages of the disease, this FOA will support research teams that have complementary expertise in glycobiology and cancer biology to focus on mechanisms that mediate alterations in glycosylation during oncogenesis.
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Limited Competition: Centers of Biomedical Research Excellence (COBRE) Phase III - Transitional Centers (P30) (PAR-17-208)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to transition the core resources and biomedical research activities of Centers of Biomedical Research Excellence (COBRE) into independence and sustainability.
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care (R18) (PAR-17-177)
  **SPONSOR:** National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Planning Grants for Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care (R34) (PAR-17-180)
  **SPONSOR:** National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Maximizing Investigators’ Research Award for Early Stage Investigators (R35) (PAR-17-190)
  **SPONSOR:** National Institute of General Medical Sciences
  Application Receipt Date(s): Multiple dates, see announcement

**OTHER FUNDING OPPORTUNITIES**
(Sponsors in bold are NIH Peer Reviewed Organizations)

- **TITLE:** AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE)
  [http://www.aacr.org/RESEARCH/RESEARCH/PAGES/AACR-PROJECT-GENIE-PARTICIPATION.ASPX#WMBuI_KaUY](http://www.aacr.org/RESEARCH/RESEARCH/PAGES/AACR-PROJECT-GENIE-PARTICIPATION.ASPX#WMBuI_KaUY)
  **SPONSOR:** American Association for Cancer Research (AACR)
  **Synopsis:** AACR Project GENIE is accepting applications for new participants from non-profit institutions directly involved in the care of cancer patients nearly a full year ahead of schedule.
  Application Receipt Date(s): May 1, 2017

- **TITLE:** Medical Research Grants: Reach Awards
  **SPONSOR:** Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)
  **Synopsis:** The purpose of the Reach Grant is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to move hypothesis-driven research into the clinic. Significant barriers exist that impede the translation of innovative and important ideas to the clinic. The Reach Grant seeks to remove one of these barriers by providing support for important preclinical projects that are necessary to move a study from the pre-clinical arena into a clinical trial. Thus, the goal of this award is to support selected late translational studies. Preference will be given to those research projects which, if funded, will likely result in the initiation of a clinical trial two to three years from the start of the project.
  Application Receipt Date(s): May 22, 2017

- **TITLE:** Paul Marks Prize for Cancer Research
  [https://www.mskcc.org/research-advantage/impact/paul-marks-prize-research](https://www.mskcc.org/research-advantage/impact/paul-marks-prize-research)
  **SPONSOR:** Memorial Sloan Kettering Cancer Center (MSKCC)
• **TITLE:** Independent Grants for Learning & Change (IGL&C): Request for Improving Health Care Capacity in Immuno-Oncology  
**SPONSOR:** Pfizer, Inc.

• **TITLE:** Independent Grants for Learning & Change (IGLC): Track 2 - Call for Grant Applications (CGA) - Patient Education in Advanced or Metastatic Breast Cancer Treatment (CGA - MBC Patient Education)  
http://www.pfizer.com/responsibility/grants_contributions/grants_process  
**SPONSOR:** Pfizer, Inc.

• **TITLE:** Independent Medical Education (IME)  
http://www.gene.com/good/grants/imed  
**SPONSOR:** F. Hoffmann-La Roche Ltd, Genentech

• **TITLE:** Unrestricted Educational Grants (Independent Medical Education Grants)  
http://www.allergan.com/responsibility/unrestricted-educational-grants  
**SPONSOR:** Allergan

• **TITLE:** Cancer Prevention and Control Programs for State, Territorial, and Tribal Organizations  
http://www.grants.gov/web/grants/view-opportunity.html?oppId=290724  
**SPONSOR:** United States Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP)

• **TITLE:** Research Grants  
https://www.worldwidecancerresearch.org/funding-for-research/  
**SPONSOR:** Worldwide Cancer Research